Zhang et al. (JAMA, Feb 2026) report that moderate caffeine consumption (2–3 cups/day) is associated with reduced dementia risk and slower cognitive decline in 130,000+ health professionals over 43 years. The 18% relative risk reduction for high consumers has generated predictable headlines. The study is well-conducted for what it is. The problem is what it is.

The reverse causation trap is 20 years deep

Prodromal dementia begins 10–20 years before diagnosis. Anosmia, dysgeusia, apathy, and sleep disturbance are early symptoms — all of which reduce the sensory reward of coffee and drive spontaneous caffeine reduction. Declining coffee intake is plausibly a symptom of incipient neurodegeneration, not a risk factor for it.

The study's own data hints at this: decaffeinated coffee is paradoxically associated with faster cognitive decline, particularly verbal memory. If coffee's non-caffeine compounds (chlorogenic acids, trigonelline, melanoidins) were protective, decaf should help. It doesn't — because decaf consumers are self-selected from the prodromal population switching away from caffeinated beverages to manage subclinical symptoms.

Standard lag-time analyses (excluding cases within 5–10 years of diagnosis) cannot fix this when the prodromal window is twice that long. You'd need to exclude 20 years of follow-up to be safe, destroying the study's statistical power.

Healthy-user bias in an already-extreme cohort

NHS and HPFS participants are health professionals — a population with education, income, health literacy, and preventive care access far exceeding population norms. Within this already-selected group, coffee drinkers systematically differ from abstainers in exercise, diet quality, social engagement, and healthcare utilization — all established dementia-protective factors.

In nutritional epidemiology, unmeasured and residual confounding routinely accounts for 20–40% relative risk distortions. The entire 18% signal sits comfortably within this range. No statistical adjustment can eliminate confounding you didn't measure.

The mechanism is mouse-deep

The proposed biological pathway — adenosine A2A receptor antagonism reducing amyloid-β accumulation — is supported by rodent models but has zero human RCT validation for cognitive endpoints. A2A antagonists (istradefylline, preladenant) have been tested in Parkinson's disease for motor symptoms, not cognition. No randomized trial has examined caffeine supplementation on dementia progression in at-risk humans. A 2010 meta-analysis found only a "trend toward protective effects" with methodological heterogeneity precluding definitive conclusions. Fifteen years later, we still lack causal evidence.

The effect size is smaller than the noise

In educated health-professional cohorts with baseline dementia incidence of ~5–8% over 20 years, an 18% relative risk reduction translates to roughly 0.9–1.4% absolute risk reduction. This is clinically marginal and sits well within the magnitude of known confounding biases in this type of study. The entire observed effect plausibly vanishes under rigorous bias correction.

What would actually settle this

An enriched RCT: recruit individuals aged 60–75 with olfactory dysfunction (UPSIT <34) and documented recent caffeine reduction — targeting the exact prodromal population. Randomize to sustained caffeine 300 mg/day vs. placebo for 36 months, measuring cognitive trajectory (PACC slope) and CSF/PET biomarkers. This converts the reverse causation liability into an enrichment strategy, directly testing whether forced caffeine continuation alters neurodegeneration when symptom-driven cessation is experimentally overridden.

Until someone runs that trial, "coffee prevents dementia" remains a correlation wearing a lab coat.

Research powered by BIOS.